Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is making waves in the pharmaceutical industry with its latest financial results for the third quarter and nine months ending on September 30, 2023.
In an impressive display of financial prowess, the company reported a substantial increase in net product revenue, reaching an astonishing $40.8 million for Q3 2023, marking a jaw-dropping 60% surge compared to the same period in 2022.
The nine-month total net revenue for 2023 also dazzled at $130.4 million, signifying a remarkable 24% increase over the prior year.
Aurinia’s financial highlights for the nine months ended September 30, 2023, set the stage for excitement. The net product revenue for this period surged to $116.2 million, showing a staggering growth rate of approximately 55% compared to 2022.
While the total net revenue for the three months ending September 30, 2023, came in at $54.5 million, it was slightly lower than the $55.8 million reported for the same period in 2022.
However, despite the fireworks in revenue, there was a dampener as Aurinia reported a net loss of $13.4 million for Q3 2023, in contrast to the net loss of $9.0 million for Q3 2022. But, there’s a silver lining.
For the nine months ending on September 30, 2023, the company managed to record a net loss of $51.1 million, which is a significant improvement from the net loss of $82.1 million for the same period in 2022.
Aurinia’s journey was marked by several operational milestones, one of the most notable being the achievement of pricing and reimbursement approvals in three of the five major European markets.
This achievement unlocked a $10 million payment from Otsuka Pharmaceutical Co. Ltd, adding a significant boost to their financial prowess.
Additionally, the company reported an impressive statistic – approximately 1,939 patients were on LUPKYNIS therapy at the end of September 2023, showcasing a remarkable 43% increase year over year.
Looking ahead, Aurinia Pharmaceuticals has exciting plans for the fiscal year 2023.
The company is narrowing its net product revenue guidance to a range of $155 – $160 million for net product sales of LUPKYNIS, a product that seems to be gaining significant traction in the market.
Despite a decrease in their cash, cash equivalents, and restricted cash and investments from $389.4 million at the end of 2022 to $338.5 million as of September 30, 2023, Aurinia firmly believes it has the financial resources necessary to fund its operations for at least the next few years.
Peter Greenleaf, the President and Chief Executive Officer of Aurinia, expressed his delight with the results, saying, “We are very pleased with our overall results for the first nine months of the year.
Reporting another strong quarter of results reinforces our ability to execute and deliver against key metrics. Our team continues to focus on business fundamentals and steady performance.”
He went on to elaborate on their focus on growing the overall LN (lupus nephritis) market and the recent $10 million milestone achieved through their collaboration partner outside the U.S., which was a result of securing pricing and reimbursement approvals in three of the five major European markets.
Aurinia Pharmaceuticals Inc’s Q3 2023 earnings report certainly packs a punch, with incredible revenue growth and operational achievements, setting the stage for a promising future in the pharmaceutical industry.